Calretinin, a more sensitive but less specific marker than α-inhibin for ovarian sex cord-stromal neoplasms -: An immunohistochemical study of 215 cases

被引:117
作者
Movahedi-Lankarani, S
Kurman, RJ
机构
[1] Johns Hopkins Univ Hosp, Dept Pathol, Div Gynecol Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ Hosp, Dept Obstet & Gynecol, Baltimore, MD 21231 USA
关键词
ovary; sex cord-stromal neoplasms; inhibin; calretinin;
D O I
10.1097/00000478-200211000-00010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Although inhibin has been shown to be a sensitive marker for ovarian sex cord-stromal and fibrous neoplasms, it may be negative in some cases. Calretinin, a mesothelial marker, has shown promise as a marker for sex cord-stromal neoplasms. The aim of this study was to evaluate and compare calretinin and inhibin as immunohistochemical markers for sex cord-stromal and fibrous neoplasms. A total of 215 ovarian neoplasms were immunostained with commercially available antibodies to calretinin and inhibin. These tumors included 87 sex cord-stromal (39 granulosa cell, 13 Sertoli-Leydig, 4 Sertoli, 9 thecomas, 14 fibrothecomas, and 8 other stromal tumors), 37 fibrous (20 fibromas, 9 adenofibromas, and 8 fibrosarcomas), 65 epithelial, 22 germ cell, and 4 miscellaneous neoplasms. The staining was evaluated on a 0-4 scale based on percentage of neoplastic cells labeling: 0 none; 1+ = 1-25%; 2+ 26-50%; 3+ = 51-75%; 4+ 76-100%. Calretinin reactivity was detected in 100% of sex cord-stromal and 90% of fibrous neoplasms, including 32 that were inhibin negative (2 granulosa cell tumors, I Sertoli-Leydig cell tumor, I thecoma, 3 fibrothecomas, 16 fibromas, 6 adenofibromas, and 3 fibrosarcomas). All four calretinin-negative fibrous neoplasms were inhibin negative. Calretinin staining was also detected in 22% of epithelial neoplasms but none of the germ cell and miscellaneous neoplasms tested. Inhibin staining was detected in 92% of sex cord-stromal neoplasms, 22% of fibrous neoplasms, 2% of epithelial neoplasms, and none of the germ cell and miscellaneous neoplasms tested. Calretinin has a 97% sensitivity and 85% specificity for sex cord-stromal and fibrous neoplasms, whereas inhibin has a 7 1 % sensitivity and 99% specificity. This study shows that both calretinin and inhibin are useful in the diagnosis of ovarian sex cord-stromal and fibrous neoplasms. Calretinin is a more sensitive but less specific immunohistochemical marker than inhibin. Calretinin is particularly useful in the diagnosis of sex cord-stromal and fibrous neoplasms that are inhibin negative. The high frequency of calretinin in fibrous neoplasms suggests that a subgroup of these neoplasms may be derived from specialized gonadal stromal cells, perhaps thecal cells.
引用
收藏
页码:1477 / 1483
页数:7
相关论文
共 35 条
[1]   Relaxin-like factor (RLF):: A new specific marker for leydig cells in the ovary [J].
Bamberger, AM ;
Ivell, R ;
Balvers, M ;
Kelp, B ;
Bamberger, CM ;
Riethdorf, L ;
Löning, T .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1999, 18 (02) :163-168
[2]  
Bertschy S, 1998, HISTOCHEM CELL BIOL, V109, P59
[3]  
Blessing K, 1998, HISTOPATHOLOGY, V32, P139
[4]  
BURGER HG, 1988, ENDOCRINOLOGY, V122, P1701
[5]   Expression of calretinin in human ovary, testis, and ovarian sex cord-stromal tumors [J].
Cao, QJ ;
Jones, JG ;
Li, MM .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2001, 20 (04) :346-352
[6]  
COSTA MJ, 1997, HUM PATHOL, V31, P67
[7]   Calretinin: A novel immunocytochemical marker for mesothelioma [J].
Doglioni, C ;
Tos, APD ;
Laurino, L ;
Iuzzolino, P ;
Chiarelli, C ;
Celio, MR ;
Viale, G .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (09) :1037-1046
[8]   MONOCLONAL-ANTIBODIES AGAINST INHIBIN REPRESENT KEY MARKERS OF ADULT GRANULOSA-CELL TUMORS OF THE OVARY EVEN IN THEIR METASTASES - A REPORT OF 3 CASES WITH LATE METASTASIS, BEING PREVIOUSLY MISINTERPRETED AS HEMANGIOPERICYTOMA [J].
FLEMMING, P ;
WELLMANN, A ;
MASCHEK, H ;
LANG, H ;
GEORGII, A .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (08) :927-933
[9]   The site of inhibin production in ovarian neoplasms [J].
Flemming, P ;
Grothe, W ;
Maschek, H ;
Petry, KU ;
Wellmann, A ;
Georgii, A .
HISTOPATHOLOGY, 1996, 29 (05) :465-468
[10]  
Gordon MD, 1998, MODERN PATHOL, V11, P769